NCT06998121

Brief Summary

Transrectal ultrasound (TRUS)-guided prostate biopsy is one of the most commonly performed urological procedures today. This technique involves the insertion of a needle through the rectal mucosa to access the prostate. While TRUS-guided biopsy demonstrates a high detection rate for prostate cancer, it also carries a significant risk of post-procedural complications, such as hematuria, rectal bleeding, urinary retention, and anemia. Compared to other biopsy methods, TRUS-guided biopsy is associated with higher rates of hospital readmissions and an increased risk of infection and sepsis. These complications contribute to elevated healthcare costs, prolonged hospital stays, increased workload for healthcare providers, heightened patient stress and anxiety levels, greater analgesic requirements, the potential for additional complications, and reduced patient satisfaction. Various non-pharmacological methods have been shown to be effective in preventing these adverse patient outcomes. One such method, which has been identified in the literature as effective, is cold application. Cold application is a widely preferred non-pharmacological intervention due to its simplicity, affordability, and accessibility. It is particularly used to reduce acute pain, edema, and bleeding. Cold therapy slows down metabolism, thereby reducing the oxygen and nutrient demands of tissues; it also limits inflammation, muscle spasm, and edema, alleviates pressure and tension on nerve endings, and decreases the conduction velocity of peripheral nerves. These effects contribute to a reduction in patients' pain, anxiety associated with pain, and bleeding. The aim of this study is to determine the effects of intrarectal ice application during transrectal ultrasound-guided prostate biopsy on pain, anxiety, cortisol levels, the incidence of complications, and hospital readmission rates.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for not_applicable prostate-cancer

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable prostate-cancer

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 31, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 19, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2026

Completed
Last Updated

March 24, 2026

Status Verified

March 1, 2026

Enrollment Period

10 months

First QC Date

May 29, 2025

Last Update Submit

March 19, 2026

Conditions

Keywords

Transrectal ultrasound (TRUS)-guided prostate biopsyintrarectal ice applicationpain, anxiety, cortisol levels

Outcome Measures

Primary Outcomes (3)

  • Anxiety

    The State Anxiety Scale : In this study, the DAQ, which is structured to measure momentary feelings, was used. Its Turkish validity and reliability was conducted by Öner and Le Compte in 1983. The DAQ consists of 20 questions on a four-point Likert scale. The statements in the DAQ are evaluated as not at all (1), a little (2), a lot (3) and completely (4). In this section, the statements are divided into direct and reversed statements. Inverted statements: 1st, 2nd, 5th, 5th, 8th, 8th, 10th, 11th, 15th, 16th, 19th, 20th items. The total score of the reversed statements is subtracted from the total score of the direct statements and the number 50, which is the invariant value of the DAQ, is added to the value obtained and the DAQ score is calculated. The scale score ranges between 20-80 and an increase in the score indicates an increase in the level of anxiety.

    12 months

  • Pain score

    Visual Analog Scale: It is a scale that provides a subjective assessment of pain on a horizontal or vertical line from 0 (no pain at all)-10 (very severe pain) to evaluate the level of pain (Wewers and Lowe, 1990).

    12 months

  • Patient Outcomes

    Patient Follow-up Form: This form will record patients' serum cortisol levels before and after the biopsy procedure, complications that develop within one week after the biopsy (rectal bleeding, haematuria, urinary retention, anaemia, infection, etc.) and whether the patient returns to the hospital during this period.

    12 months

Study Arms (2)

experimental

EXPERIMENTAL

Patients included in the study group will receive intrarectal ice application by researchers (E.K.D. and M.B.) in addition to the outpatient clinic's routine treatment and care practices. For each patient, a new glove (size 8) will be filled with water and frozen to obtain the cold application material. Immediately before the procedure, the lubricated ice will be placed in the patient's rectum and held there for 5 minutes (Caliskan and Mutlu, 2015). Pain and anxiety will be assessed in all patients during and after the procedure. At the end of the prostate biopsy, 2 ml of blood will be collected again from the patients to measure serum cortisol levels. The occurrence of complications will be determined by researchers (E.K.D. and G.B.) via telephone during the procedure and one week later. Additionally, when researchers call the patient one week later, they will inquire about any subsequent hospital visits during that period. All information will be recorded on the necessary forms.

Other: Intrarectal ıce application

contrl

NO INTERVENTION

At the outpatient clinic where the study was conducted, oral antibiotic treatment (2x1 Iesef 1 g) was started 24 hours before the prostate biopsy and continued until the dose was completed. A B.T. ENEMA is performed the night before the procedure and at 6:00 a.m. on the day of the procedure. During the procedure, biopsy samples are taken from 12 different areas using a fine needle guided by transrectal ultrasound. Patients who experience pain after the procedure are advised to take oral analgesics (paracetamol). Additionally, patients are informed about precautions to take after the procedure (e.g., seeking medical attention in cases of fever ≥38.5°C and excessive haematuria, avoiding spicy foods for two weeks, etc.). Furthermore, no measures are taken in the outpatient clinic to control pain or anxiety during prostate biopsy. Patients in the control group will receive the outpatient clinic's routine treatment and care. Translated with DeepL.com (free version)

Interventions

Patients included in the study group will receive intrarectal ice application by researchers (E.K.D. and M.B.) in addition to the outpatient clinic's routine treatment and care practices. For each patient, a new glove (size 8) will be filled with water and frozen to obtain the cold application material. Immediately before the procedure, the lubricated ice will be inserted into the patient's rectum and held in place for 5 minutes (Caliskan and Mutlu, 2015).

experimental

Eligibility Criteria

Age18 Years+
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsThe procedure is specific to men because a prostate biopsy will be performed.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who agree to participate in the study,
  • Patients over the age of 18
  • Patients who are conscious, oriented, and cooperative,
  • Patients who have no communication problems,
  • Patients who are scheduled to undergo their first prostate biopsy under transrectal ultrasound guidance,
  • Patients who have no mental disorders,
  • Patients who have not been diagnosed with anxiety disorder,
  • Patients not taking medication for anxiety control.

You may not qualify if:

  • Patients who refuse to participate in the study,
  • Patients under the age of 18
  • Patients who are conscious, oriented, and uncooperative,
  • Patients with communication problems,
  • Patients who have not undergone transrectal ultrasound-guided prostate biopsy,
  • Patients who have previously undergone prostate biopsy,
  • Patients with mental disorders,
  • Patients diagnosed with anxiety disorder,
  • Patients taking medication for anxiety control.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Mersin Unıversıty

Mersin, Turkey (Türkiye)

RECRUITING

Mersin Unıversıty

Mersin, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Prostatic NeoplasmsPainAnxiety Disorders

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Study Officials

  • GAMZE BOZKUL

    Tarsus University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

ELİFE KETTAŞ DÖLEK

CONTACT

ELİFE KETTAŞ DÖLEK

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
When it is decided to perform prostate biopsy on patients at the urology outpatient clinic, the researcher (M.B.) will evaluate the patients' eligibility for inclusion in the study. Patients will be assigned to groups using the block randomisation method. Patients will be divided into the study and control groups according to the permutations (ABBA, BABA, etc.) in the randomisation list created by a biostatistician not involved in the study using a computer. After the randomisation list is created, the status of groups A and B as representing the study or control group will be determined by lottery. The coordinating researcher (G.A.U.), who will not be involved in the data collection process of the study, will write numbers from 1 to 96 on the envelope, corresponding to the sample size, and add the letters A or B, representing the groups, inside the envelopes. When the researcher (E.K.D.) visits the patient, they will open the numbered envelope received from the coordinating researcher
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: As a randomised controlled clinical trial, the study population will consist of patients who visit the Urology Outpatient Clinic at Mersin University Hospital and who will undergo transrectal ultrasound-guided prostate biopsy.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 29, 2025

First Posted

May 31, 2025

Study Start

June 1, 2025

Primary Completion

March 19, 2026

Study Completion

May 15, 2026

Last Updated

March 24, 2026

Record last verified: 2026-03

Locations